Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948760 · ClinicalTrials.gov registry record · NA
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D
A NA study of Type 1 Diabetes, sponsored by Mark D. DeBoer, MD, MSc., MCR.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06948760 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Mark D. DeBoer, MD, MSc., MCR. The registered enrollment target is 20 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06948760, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Mark D. DeBoer, MD, MSc., MCR.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Conditions Studied
Interventions
- DEVICE Control-IQ insulin pump with Lyumjev insulin
- DEVICE Control-IQ insulin pump with Humalog or Novolog
Study Locations (1)
Virginia
- University of Virginia Center for Diabetes Technology - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948760
The ClinicalTrials.gov registry entry for NCT06948760 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Mark D. DeBoer, MD, MSc., MCR, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Control-IQ insulin pump with Lyumjev insulin is the first listed.
NCT06948760 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06948760 about?
NCT06948760 is a clinical study titled "Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D". A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
What is the current status of trial NCT06948760?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-07-23. Estimated completion is 2026-03-31.
What conditions does trial NCT06948760 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06948760?
The interventions under investigation include: Control-IQ insulin pump with Lyumjev insulin (DEVICE), Control-IQ insulin pump with Humalog or Novolog (DEVICE).
Who is sponsoring clinical trial NCT06948760?
This trial is sponsored by Mark D. DeBoer, MD, MSc., MCR, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948760 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.